Ingen internetforbindelse — viser den gemte version af siden.

CSL Ltd

AUAUD
← Til Screeneren

CSL Ltd (US:CMXHF) — Biotechnology. Antal børser, hvor selskabets aktier handles: 2. På denne side — kurs og diagram, udbytte, største aktionærer og historik over antal aktier.

Om Virksomheden

Websted
csl.com.au
Investorrelationer
investors.csl.com/
Sektor
Healthcare · Biotechnology
Hovedkontor
Melbourne, Australia
Administrerende Direktør
Gordon Naylor BEng
Ansatte
29 000
Grundlagt
1994
Udestående Aktier
479.88 mio.
Free Float
478.53 mio.
Markedsværdi
87.08 mia. AUD
Insidere
0.02%
Institutionelle Investorer
38.27%
Juridisk Form
R4KK
ISIN
AU000000CSL8
LEI
529900ECSECK5ZDQTE14
P/E
underskud
P/B
4.38
Udbetalingsgrad
underskud
FCF
2.23 mia. USD
Udbetaling / FCF
70%
Gæld
10.9 mia. USD
3.5 år FCF
Udbyttestreak
31 år
Indtjening, FCF og udbetalt udbytte — for de 12 måneder frem til 30.06.2026 (selskabets seneste rapport).
NAV
30.90 USD · P/NAV 4.43
Balancedato30.06.2026
Aktiver33.6 mia. USD
− Forpligtelser17.3 mia. USD
= Total Egenkapital16.3 mia. USD
− Ikke-Kontrollerende Interesser1.51 mia. USD
= NAV (aktiekapital i selskabets aktionærer)14.8 mia. USD
− Goodwill6.37 mia. USD
− Immaterielle Aktiver4.60 mia. USD
= Materiel NAV3.83 mia. USD
Aktier478 911 979
NAV pr. Aktie30.90 USD
Håndgribelig NAV pr. Aktie8.00 USD
Aktiekurs (CMXHF)136.90 USD
P/NAV4.43
NAV-Historie
BalancedatoNAVNAV pr. Aktie
30.06.202614.8 mia. USD30.90 USD
30.06.202519.3 mia. USD39.93 USD
30.06.202417.4 mia. USD35.93 USD
Beskrivelse

CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. The company's therapeutic areas includes Immunoglobulins, Immunology, Immunology Haematology, Cardiovascular and Renal, and Vaccines. It also licenses CSL intellectual property. It also develops vaccines for the prevention of infectious disease. The company has strategic collaboration with Dutch biotech company VarmX BV for the development of VMX-C001 to help restore blood coagulation in patients requiring urgent surgery; and Alentis Therapeutics AG to develop and commercialise lixudebart for rare kidney and liver diseases. The company was formerly known as Commonwealth Serum Laboratories Limited and later changed its name to CSL Limited in October 1991. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

annonce

Børser og Tickere

BørsTickerValutaPrisType
AU Australian Securities ExchangeCSL primærAUD196.7 +0.29%almindelige aktier
US USA StocksCMXHF OTCUSD136.9 +0.70%almindelige aktier

Kurs over 3 Måneder

stigningsdag faldsdag udbyttets ex-dato udbetalingsdatoHold musen over / tryk på en dag — åbnings-, luknings-, højeste og laveste kurs

Udbytte

Pr. År, AU:CSL: 4.0536 AUD (2 udb.)

CSL Ltd (CSL) udbetaler udbytte to gange om året. Pr. År (12 måneder op til og med den senest annoncerede betaling): 4.0536 AUD pr. Aktie (betalinger: 2). Det svarer til cirka 2.06% af den nuværende aktiekurs. Baseret på betalingshistorikken forventes næste ex-udbyttedato omkring 10.03.2027. Uafbrudt udbyttehistorik: 31 år.

Ex-DatoUdbetalingBeløb%TypeTicker
2026-09-09—2.2438 AUD1.3/2.3 %halvårligAU:CSL
2026-03-10—1.8098 AUD1.3/3.0 %halvårligAU:CSL
2025-09-09—2.4508 AUD1.1/2.1 %halvårligAU:CSL
2025-03-10—2.0727 AUD0.8/1.6 %halvårligAU:CSL
2024-09-09—2.1746 AUD0.7/1.3 %halvårligAU:CSL
2024-03-11—1.7989 AUD0.6/1.3 %halvårligAU:CSL
2023-09-11—2.0078 AUD0.7/1.3 %halvårligAU:CSL
2023-03-09—1.6215 AUD0.5/1.1 %halvårligAU:CSL
2022-09-06—1.7583 AUD0.6/1.1 %halvårligAU:CSL
2022-03-07—1.4229 AUD0.6/0.6 %halvårligAU:CSL

Største Ejere

EjerAndelAktierRapportdato
VANGUARD STAR FUNDS-Vang…1.49%7.16 mio.2026-07-31
VANGUARD TAX-MANAGED FUN…0.99%4.75 mio.2026-06-30
iShares Trust-iShares Co…0.75%3.6 mio.2026-08-31
Fidelity Concord Street…0.39%1.89 mio.2026-07-31
iShares Trust-iShares MS…0.36%1.72 mio.2026-08-31
J.P. Morgan Exch-Trd Fd.…0.3%1.45 mio.2026-07-31
Fidelity Salem Street TR…0.29%1.38 mio.2026-07-31
iShares Trust-iShares MS…0.28%1.35 mio.2026-08-31
VANGUARD Intl Eqy. INDEX…0.24%1.16 mio.2026-07-31
SCHWAB STRATEGIC TRUST-S…0.22%1.08 mio.2026-05-31
Pacer Advisors, Inc.0.08%369 7742026-06-30
Naylor (Gordon) (Directo…≈0.01%40 8192026-05-26
McKenzie (Paul F) (Chief…≈0.01%31 0532025-09-01
McNamee (Brian Anthony)…≈0.01%30 5612026-08-21
Linton (Joy) (Chief Fina…≈0%15 0962025-06-30
Watkins (Alison Mary) (I…≈0%6 9892026-08-21
Clark (Megan Elizabeth)…≈0%5 7182025-08-22
Schmeltz (Andy) (Other E…≈0%5 0672025-06-30
Hewson (Carolyn Judith)…≈0%4 1312026-08-21
Price (Cameron Bruce) (I…≈0%3 5592026-08-21
Daniels (Brian M.D.) (No…≈0%3 4002025-11-18